Valoctocogene Roxaparvovec

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Keywords

formulary management/P & T gene therapy drug information

Get full access to this article

View all access options for this article.

References

Roctavian (valoctocogene roxaparvovec-rvox) [prescribing information]. BioMarin Pharmaceutical Inc; June 2023.

Srivastava

Santagostino

Dougall

, et al. WFH guidelines for the management of hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26:1-158. doi:10.1111/hae.14046

Purple Book: Database of Licensed Biological Products . Food and Drug Administration. Updated October 24, 2023. Accessed October 30, 2023. https://purplebooksearch.fda.gov/

Hemlibra (emicizumab-kxwh) [prescribing information]. Genentech Inc; March 2023.

Mahlangu

Kaczmarek

von Drygalski

, et al.; GENEr8-1 Trial Group. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. New Engl J Med. 2023;388:694-705. doi:10.1056/NEJMoa2211075

Ozelo

Mahlangu

Pasi

, et al.; GENEr8-1 Trial Group. Valoctocogene roxaparvovec gene therapy for hemophilia A. New Engl J Med. 2022;386:1013-1025. doi:10.1056/NEJMoa2113708

Pasi

Rangarajan

Mitchell

, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. New Engl J Med. 2020;382:29-40. doi:10.1056/NEJMoa1908490

Pasi

Laffan

Rangarajan

, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27:947-956. doi:10.1111/hae.14391

Rangarajan

Walsh

Lester

, et al. AAV5-factor VIII gene transfer in severe hemophilia A. New Engl J Med. 2017;377:2519-2530. doi:10.1056/NEJMoa1708483

10.

Fonck

Arens

, et al. Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy. Gene Ther. 2023;30:581-586. doi:10.1038/s41434-022-00318-5

11.

Witten

BLA approval letter: Roctavian (valoctocogene roxaparvovec-rvox) (BLA 125720/0). Food and Drug Administration. Published June 30, 2023. Accessed October 30, 2023. https://www.fda.gov/media/169963/download